Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 30, 2023

CHMP recommends approval of Bristol Myers Squibb’s Reblozyl

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bristol Myers Squibb’s Reblozyl (luspatercept) for adult patients with anemia associated with non‑transfusion-dependent (NTD) beta thalassemia.

CHMP recommends approval of Bristol Myers Squibb’s Reblozyl